Skip to main content

Table 1 Summary of AEs, SAEs, AESIs, and ADRs reported in patients receiving R-chemo

From: Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

Baseline characteristics

AE (any grade), n (%)

AE (grade 3–4), n (%)

SAE, n (%)

AESI, n (%)

ADR, n (%)

Total (n = 279)

267(95.7)

147(52.7)

47(16.8)

46 (16.5)

226 (81.0)

Age, y

19–60 (n = 160)

206 (95.8)

103 (47.9)

30 (14.0)

32 (14.9)

172 (80.0)

61–80 (n = 109)

22 (95.7)

16 (69.6)

7(30.4)

6 (26.1)

21(91.3)

≤18 to >80 (n = 10)

42 (95.5)

30 (68.2)

11(25.0)

9 (20.5)

36 (81.8)

History of diseases

Heart diseases (n = 23)

10 (100.0)

5 (50.0)

3 (30.0)

2 (20.0)

10 (100.0)

Liver diseases (n = 44)

152 (95.0)

76 (47.5)

22 (13.8)

22 (13.8)

126 (78.8)

No heart or liver diseases (n = 215)

105 (96.3)

66 (60.6)

22 (20.2)

22 (20.2)

90 (82.6)

  1. ADR adverse drug reaction, AE adverse event, AESI adverse event of special interest, chemo chemotherapy, SAE severe adverse event, R rituximab, y year